Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Rotschafer

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Drug Intelligence & Clinical Pharmacy|January 1, 1986
High-dose moxalactam in gram-negative pneumoniaB H Ackerman, J C Rotschafer, R W Tofte
Critical Care Medicine|April 9, 2001
Intensive care unit antimicrobial resistance and the role of the pharmacistK H Ibrahim, B Gunderson, J C Rotschafer
Drug Intelligence & Clinical Pharmacy|June 1, 1988
Use of vancomycin and tobramycin polymethylmethacrylate impregnated beads in the management of chronic osteomyelitisD M Scott, J C Rotschafer, F Behrens
Clinical Pharmacy|August 1, 1988
Aminoglycoside pharmacokinetic monitoring: an integral part of patient care?K A Rodvold, H Zokufa, J C Rotschafer
Minnesota Medicine|December 1, 1986
Imipenem: a novel carbapenem antibioticL M Dark, H Zokufa, J C Rotschafer
Clinical Pharmacy|August 1, 1987
Routine monitoring of serum vancomycin concentrations: can waiting be justified?K A Rodvold, H Zokufa, J C Rotschafer
Southern Medical Journal|November 1, 1989
Suboptimal effect of daptomycin in the treatment of bacteremiasM W Garrison, J C Rotschafer, K B Crossley
Pharmacotherapy|July 3, 1999
Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal diseaseA L Somerville, D H Wright, J C Rotschafer
Diagnostic Microbiology and Infectious Disease|May 1, 1995
Therapeutic options for cefotaxime in the management of bacterial infectionsJ K Raddatz, B E Ostergaard, J C Rotschafer
The Annals of Pharmacotherapy|July 1, 1992
Selective decontamination of the digestive tract in intensive care patients: review and commentaryE C Gomez, S J Markowsky, J C Rotschafer
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Drug Intelligence & Clinical Pharmacy|January 1, 1986
High-dose moxalactam in gram-negative pneumoniaB H Ackerman, J C Rotschafer, R W Tofte
Critical Care Medicine|April 9, 2001
Intensive care unit antimicrobial resistance and the role of the pharmacistK H Ibrahim, B Gunderson, J C Rotschafer
Drug Intelligence & Clinical Pharmacy|June 1, 1988
Use of vancomycin and tobramycin polymethylmethacrylate impregnated beads in the management of chronic osteomyelitisD M Scott, J C Rotschafer, F Behrens
Clinical Pharmacy|August 1, 1988
Aminoglycoside pharmacokinetic monitoring: an integral part of patient care?K A Rodvold, H Zokufa, J C Rotschafer
Minnesota Medicine|December 1, 1986
Imipenem: a novel carbapenem antibioticL M Dark, H Zokufa, J C Rotschafer
Clinical Pharmacy|August 1, 1987
Routine monitoring of serum vancomycin concentrations: can waiting be justified?K A Rodvold, H Zokufa, J C Rotschafer
Southern Medical Journal|November 1, 1989
Suboptimal effect of daptomycin in the treatment of bacteremiasM W Garrison, J C Rotschafer, K B Crossley
Pharmacotherapy|July 3, 1999
Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal diseaseA L Somerville, D H Wright, J C Rotschafer
Diagnostic Microbiology and Infectious Disease|May 1, 1995
Therapeutic options for cefotaxime in the management of bacterial infectionsJ K Raddatz, B E Ostergaard, J C Rotschafer
The Annals of Pharmacotherapy|July 1, 1992
Selective decontamination of the digestive tract in intensive care patients: review and commentaryE C Gomez, S J Markowsky, J C Rotschafer
Pageof 9